| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Purity: | >98% |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product name | Mildronate |
| CAS number | 76144-81-5 |
| Molecular formula | C6H14N2O2 |
| Molecular weight | 146.18756 |
| Appearance | White Powder |
| Purity | 99.0% |
| Function | 1. It can improve the energy metabolism process of cardiomyocytes, inhibit carnitine-dependent fatty acid oxidation, strengthen intracellular glucose metabolism, provide energy to tissues through anaerobic fermentation, improve myocardial ischemia and hypoxia symptoms, and can be used in combination with other drugs (such as vasodilators, diuretics, etc.) for the treatment of ischemic heart disease. 2. It can promote the redistribution of blood in the heart and cerebral ischemic regions, and is used for the treatment of various acute and chronic cerebral blood supply disorders. 3.It is improving the process of fat metabolism, the drug can improve people's working ability and alleviate psychological and physiological overstress syndrome. Athletes can improve their sports performance by taking the drug during training and competition. |
| Description | M'eldonium (also known as THP, met-88 and mildronate) is a new heart protective drug.Developed by latovia organic synthesis, first marketed in the former Soviet union in 1989 by Grindeks, it is a structural analogue of carnitine, chemically known as 3- (2, 2, 2-trimethylenehydrazol) propionate dihydrate.It has been registered and listed in more than 20 countries, including Russia, Turkey, India and Romania. Mildronate is a novel cardioprotective drug that was first developed by the Latvian Institute of Organic Synthesis with a novel structure. It was first marketed by Grindeks in the former Soviet Union in 1989 and is currently sold in La Rovia, Russia, Ukraine, Belarus and Azerbaijan The drug is a structural analogue of carnitine, which competes with carnitine for γ-trimethylaminobutylase hydroxylase and reduces the concentration of free carnitine and long-chain acetylcarnitine in cells, thus inhibiting the carnitine-dependent fatty acid oxidation process At present, the traditional clinical commonly used drugs for the treatment of myocardial ischemia are the following categories: nitrate beta blockers Calcium channel blockers and fall hematic fat, etc The mechanism of action of them mainly relax vascular smooth muscle, vascular smooth muscle and coronary artery expansion, reduce myocardial oxygen consumption and reducing blood fat Mortality from coronary heart disease patients remain high Metabolic disorders during myocardial ischemia/reperfusion have always been highly concerned by medical workers. In recent years, the role of drugs to improve myocardial metabolism in the anti-myocardial ischemia/reperfusion injury has been paid much attention by many scholars. The action site of meldonzid is in mitochondria, which improves myocardial energy metabolism at the cellular level Because of the obvious difference between these drugs and other antiischemia drugs, they are also called cellular antiischemia drugs |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}